Boston Life Sciences Therafectin
Executive Summary
Company plans to submit data from a second Phase III trial in an amendment to its NDA for amiprilose in the next few weeks, the company said. FDA's Arthritis Advisory Committee agreed at a 1994 meeting that a positive pivotal trial of the synthetic carbohydrate for rheumatoid arthritis required replication in a second trial...